Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Higher IL-15 levels are linked to more severe hair loss in alopecia areata.

IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.

Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

Deleting Snai2 and Snai3 causes fatal autoimmunity.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

Enhancing Tregs can protect against alopecia areata.

LONRF1 is important for oxidative damage response and tissue remodeling during wound healing.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Igf1r helps regulate hair growth cycles.

miR-203a-3p helps hair follicle stem cells become specialized by targeting Smad1.

Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.

The conclusion is that the IL-6/STAT3 activation affects p63 expression in healing wounds, which may help in hair follicle regeneration.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.

Targeting IL-17 could help treat pattern hair loss.

The study suggests that changes in immune system receptors and their interaction with a cell component may be important in the development of a type of hair loss condition.

CDP is crucial for lung and hair follicle cell development.

p120-catenin helps control skin inflammation by regulating cadherin levels.

Higher CRHR1 levels in AA patients lead to increased inflammation.